Clinical Trial Update: Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE. [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study of Pactimibe (CS-505) for reducing progression of carotid artery disease was terminated. The update summarizes the observed efficacy and safety …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• CS-505 (Pactimibe) (Pactimibe)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Atherosclerosis, Heterozygous Familial Hypercholesterolemia | Phase 2, Phase 3 | Status: TERMINATED